Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Table 2 Incidence of DR at Each Landmark Time Assessment in OPTiM Patients Treated with Talimogene Laherparepvec and GM-CSF^a

Landmark Time, Months	Patients Alive, n	DR Achieved, n	HR for OS in Patients with DR Versus Those Without, HR (95% CI)	Adjusted HR for OS in Patients with DR Versus Those Without HR (95% CI)^b
9	335	22	0.07 (0.01–0.48)	0.07 (0.01–0.54)
12	304	36	0.05 (0.01–0.33)	0.05 (0.01–0.35)
18	236	50	0.11 (0.03–0.44)	0.11 (0.03–0.47)

DR durable response, GM-CSF granulocyte macrophage-colony stimulating factor, HR hazard ratio, ITT intent-to-treat, OS overall survival
^aAnalysis was performed in ITT population of OPTiM
^bAdjusted for disease stage (stage IIIB, IIIC, IVM1a versus stage IVM1b, IVM1c) and line of therapy (first-line versus second-line)